Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Jun;85(2):547–555. doi: 10.1111/j.1476-5381.1985.tb08892.x

The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.

G Allan, M J Follenfant, P Lidbury, P L Oliver, B J Whittle
PMCID: PMC1916618  PMID: 3896365

Abstract

9 beta-Methyl carbacyclin (9 beta Me; ciprostene) is a synthetic, chemically stable analogue of prostacyclin (PGI2; epoprostenol). The platelet anti-aggregating and cardiovascular effects of 9 beta Me have been compared to PGI2 in anaesthetized monkeys and dogs. In addition, their haemodynamic effects have been compared in open-chest anaesthetized dogs and conscious dogs. Intravenous infusion of 9 beta Me and PGI2 to the anaesthetized monkey resulted in a dose-dependent hypotension, tachycardia and inhibition of ex vivo ADP-induced platelet aggregation. 9 beta Me was 72 times less active than PGI2 both as a hypotensive and anti-aggregating agent. Intravenous infusion of 9 beta Me and PGI2 to the anaesthetized beagle dog resulted in a qualitatively similar haemodynamic profile. Thus both substances induced a dose-dependent hypotension accompanied initially by a slightly increased heart rate, a dose-dependent increase in cardiac output, stroke volume and an increased peak LV dP/dt. At the higher doses studied, the initial increases in the parameters measured were succeeded by dose-dependent falls. 9 beta Me was 76 times less active than PGI2 as a hypotensive agent. In the anaesthetized greyhound, a dose-dependent anti-aggregating and hypotensive effect was seen with either drug, with 9 beta Me being 23 and 40 times less active than PGI2, respectively. Intravenous infusion of 9 beta Me and PGI2 to the conscious beagle dog induced a dose-dependent hypotension and a variable effect on heart rate. 9 beta Me was 33 times less active than PGI2 as an hypotensive agent.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chapple D. J., Dusting G. J., Hughes R., Vane J. R. Some direct and reflex cardiovascular actions of prostacyclin (PGI2) and prostaglandin E2 in anaesthetized dogs. Br J Pharmacol. 1980 Mar;68(3):437–447. doi: 10.1111/j.1476-5381.1980.tb14557.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chiavarelli M., Moncada S., Mullane K. M. Prostacyclin can either increase or decrease heart rate depending on the basal state. Br J Pharmacol. 1982 Jan;75(1):243–249. doi: 10.1111/j.1476-5381.1982.tb08779.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. FitzGerald G. A., Friedman L. A., Miyamori I., O'Grady J., Lewis P. J. A double blind placebo controlled crossover study of prostacyclin in man. Life Sci. 1979 Aug 20;25(8):665–672. doi: 10.1016/0024-3205(79)90507-1. [DOI] [PubMed] [Google Scholar]
  4. Gimson A. E., Langley P. G., Hughes R. D., Canalese J., Mellon P. J., Williams R., Woods H. F., Weston M. J. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet. 1980 Jan 26;1(8161):173–175. doi: 10.1016/s0140-6736(80)90661-3. [DOI] [PubMed] [Google Scholar]
  5. Hassan S., Pickles H., Fish A., Burke C., Warrington S., O'Grady J. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man. Br J Clin Pharmacol. 1982 Sep;14(3):369–377. doi: 10.1111/j.1365-2125.1982.tb01993.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hintze T. H., Kaley G. Ventricular receptors activated following myocardial prostaglandin synthesis initiate reflex hypotension, reduction in heart rate, and redistribution of cardiac output in the dog. Circ Res. 1984 Mar;54(3):239–247. doi: 10.1161/01.res.54.3.239. [DOI] [PubMed] [Google Scholar]
  7. Hintze T. H., Martin E. G., Messina E. J., Kaley G. Prostacyclin (PGI2) elicits reflex bradycardia in dogs: evidence for vagal mediation. Proc Soc Exp Biol Med. 1979 Oct;162(1):96–100. doi: 10.3181/00379727-162-40625. [DOI] [PubMed] [Google Scholar]
  8. Hintze T. H., Panzenbeck M. J., Messina E. J., Kaley G. Prostacyclin (PGI2) lowers heart rate in the conscious dog. Cardiovasc Res. 1981 Sep;15(9):538–546. doi: 10.1093/cvr/15.9.538. [DOI] [PubMed] [Google Scholar]
  9. Mason D. T. Usefulness and limitations of the rate of rise of intraventricular pressure (dp-dt) in the evaluation of myocardial contractility in man. Am J Cardiol. 1969 Apr;23(4):516–527. doi: 10.1016/0002-9149(69)90005-8. [DOI] [PubMed] [Google Scholar]
  10. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  11. O'Grady J., Hedges A., Whittle B. J., Al-Sinawi L. A., Mekki Q. A., Burke C., Moody S. G., Moti M. J., Hassan S. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man. Br J Clin Pharmacol. 1984 Dec;18(6):921–933. doi: 10.1111/j.1365-2125.1984.tb02565.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. O'Grady J., Warrington S., Moti M. J., Bunting S., Flower R., Fowle A. S., Higgs E. A., Moncada S. Effects of intravenous infusion of prostacyclin (PGI2) in man. Prostaglandins. 1980 Feb;19(2):319–332. doi: 10.1016/0090-6980(80)90030-1. [DOI] [PubMed] [Google Scholar]
  13. Pickles H., O'Grady J. Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man. Br J Clin Pharmacol. 1982 Aug;14(2):177–185. doi: 10.1111/j.1365-2125.1982.tb01959.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Randall W. C., Armour J. A. Regional vagosympathetic control of the heart. Am J Physiol. 1974 Aug;227(2):444–452. doi: 10.1152/ajplegacy.1974.227.2.444. [DOI] [PubMed] [Google Scholar]
  15. Smith M. C., Danviriyasup K., Crow J. W., Cato A. E., Park G. D., Hassid A., Dunn M. J. Prostacyclin substitution for heparin in long-term hemodialysis. Am J Med. 1982 Nov;73(5):669–678. doi: 10.1016/0002-9343(82)90409-0. [DOI] [PubMed] [Google Scholar]
  16. Szczeklik J., Szczeklik A., Nizankowski R. Haemodynamic changes induced by prostacyclin in man. Br Heart J. 1980 Sep;44(3):254–258. doi: 10.1136/hrt.44.3.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Warrington S. J., Smith P. R., O'Grady J. Noninvasive assessment of the cardiovascular effects of prostacyclin (PGI2) in man. Eur J Cardiol. 1980;12(2):73–80. [PubMed] [Google Scholar]
  18. Whittle B. J., Moncada S. Pharmacological interactions between prostacyclin and thromboxanes. Br Med Bull. 1983 Jul;39(3):232–238. doi: 10.1093/oxfordjournals.bmb.a071825. [DOI] [PubMed] [Google Scholar]
  19. Whittle B. J., Moncada S., Whiting F., Vane J. R. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins. 1980 Apr;19(4):605–627. doi: 10.1016/s0090-6980(80)80010-4. [DOI] [PubMed] [Google Scholar]
  20. Zucker I. H., Cornish K. G. The Bezold-Jarisch in the conscious dog. Circ Res. 1981 Oct;49(4):940–948. doi: 10.1161/01.res.49.4.940. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES